Table 1.

Differential expression of RNA of AR-interacting proteins cancer progression.

A) AR-interacting proteins differentially expressed between metastasis and localised PCa (bulk sequencing)

FOXG1, AURKA, CDKN3, TPX2, MCM2, SRD5A1, APOBEC3B, CDC7, CDC25B, HEY1, CCNA2, PROX1, CDC25A, MCM4, SQSTM1, CCNE1, SOX4, HMGB2, BRCA1, PSMC3IP, MUC1, FEN1, CDT1, CDKN1C, E2F1, CRABP2, SPEN, MED14, H2AZ1, E2F3, SMARCA4, ITGB3BP, TRIP13, TSC2, MCM8, TBL1XR1, CTNNB1, E2F2, RPL7, MCM10, RORA, PIAS2, PRMT1, PRAME, SF3A1, FOXO1, APPBP2, NQO1, PIAS1, LMO4, AKR1C3, HSD17B11, IDE, BCL11A, HDAC4, NCOA4, NR2F2, LINC00312, ANP32A, CDK7, RORC, UBR5, GSN, SIN3A, JAZF1, LATS2, HIPK3, JUN, TP53, NR4A3, TRIP6, RORB, PRMT6, GADD45B, CITED2, CCND1, RB1, SMARCA2, SPDEF, SVIL, SRD5A2, PTEN, FLNA, DDX17, GATA3, PGR, TGFB1I1, DUSP1, CDK6, PLAGL1, FHL2, CAV1, ESRRG, ESR1, NR4A2, TCF21, TAGLN.

B) AR-interacting proteins differentially expressed between localised PCa and benign (bulk sequencing)

ESRRG, FKBP5, CRABP2, BCL11A, TBL1X, PPARGC1A, PGR, GATA3, PPARG, RORB.